
October 30, 2025
Key Year-over-Year Highlights:
- Gross Margin Expansion: Increased to 88%, up from 71%, representing a 17-point improvement.
- Operating Loss Reduced by 65%: Narrowed to $439,000, from $1.25 million in 2024.
- Net Loss Reduced by 63%: Improved to $482,000, compared to $1.31 million last year.
- Deferred Revenue Growth: Rose 186% to $582,000, from $203,000 in 2024, reflecting secured multi-year customer contracts and strong adoption of the Map D platform.
- Total Assets Up +92%: Grew to $2.17 million, from $1.13 million a year earlier.
Margin Expansion, and Operational Improvements Ahead of Eventdex Acquisition
Nextech3D.ai (CSE:NTAR)(OTCQB:NEXCF)(FSE:1SS), an AI-first technology company specializing in AI event management through its flagship Map D and Eventdex platforms, 3D modeling, and spatial computing, is pleased to announce its financial results for the quarter ended September 30, 2025.
20% Sequential Quarter-over-Quarter Growth Marks a New Growth Curve Driven by The company's AI Event Suite (Q2 vs. Q1 2025)
Nextech3D.ai delivered solid quarter-over-quarter sequential performance, underscoring the continued strength of its high-margin event technology business.
- Revenue increased 20% sequentially, rising to $390,755 in Q2 2025, up from $325,000 in Q1 2025 marking the beginning of a new growth curve.
- Deferred revenue up +186% year over year from $203,000 to $521,000
- Gross margins remained strong at 88%, supported by higher contributions from the Map D platform and continued AI-driven workflow efficiencies.
- The Company maintained disciplined cost controls, driving operational leverage and improved profitability.
Year-over-Year Comparison (Sep 2025 vs. Sep 2024)
While total revenue declined 48% year-over-year from $756,476 in 2024 to $390,755 in 2025, this reduction reflects the planned conclusion of Nextech's Amazon 3D modeling contract in Q4 2024. This strategic transition allowed the Company to fully refocus on its higher-margin AI and event-technology ecosystem, which is now driving sustainable growth and profitability.
Key Year-over-Year Highlights:
- Gross Margin Expansion: Increased to 88%, up from 71%, representing a 17-point improvement.
- Operating Loss Reduced by 65%: Narrowed to $439,000, from $1.25 million in 2024.
- Net Loss Reduced by 63%: Improved to $482,000, compared to $1.31 million last year.
- Deferred Revenue Growth: Rose 186% to $582,000, from $203,000 in 2024, reflecting secured multi-year customer contracts and strong adoption of the Map D platform.
- Total Assets Up +92%: Grew to $2.17 million, from $1.13 million a year earlier.
- Accounts Payable Down 32%: Reduced to $3.0 million, from $4.4 million, demonstrating disciplined cash management and operational efficiency.
Strategic Growth Outlook
The acquisition of Eventdex, which closed in Q3 2025, marks the acceleration of Nextech3D.ai's next growth phase. Eventdex generated approximately $700,000 in revenue in 2024 and brings a strong customer base, complementary product suite, and recurring revenue model.
Together with Map D, the combined companies now serve over 550 customers, creating opportunities to cross-sell products across a unified event technology ecosystem that includes registration, ticketing, mobile apps, floor mapping, AI matchmaking, and blockchain ticketing.
CEO Commentary - Evan Gappelberg, CEO of Nextech3D.ai
"This quarter's results show meaningful progress on all fronts - profitability, margins, and recurring revenue. The conclusion of our Amazon contract in Q4 2024 was a strategic turning point that allowed us to fully commit to our AI-first event technology model. With Eventdex now integrated and demand accelerating, we see a clear path to sustainable growth through 2026 and beyond."
"With improved gross margins to 90%, operating costs cut by more than 60%, we narrowed our net loss by over 70% and believe we have now firmly set the stage for profitability. These results reflect the discipline, focus and hard work of our team as we have streamlined operations and prioritized scalable, high-value product lines and revenue growth."
About Nextech3D.ai
Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:1SS) is an AI-first technology company developing advanced solutions for event management, 3D modeling, and spatial computing. Through its flagship Map D and Eventdex platforms, Nextech3D.ai powers thousands of events annually with interactive floor mapping, registration, ticketing, mobile apps, AI matchmaking, and now, blockchain ticketing and accreditation.
For further information, please visit: www.Nextech3D.ai.
See full report on SEDAR
Investor Relations: investors@nextechar.com
For more information, visit Nextech3D.ai.
Sign up for Investor News and Info - Click Here
For more information and full report go to
For further information, please contact:
Nextech3D.ai
Evan Gappelberg /CEO and Director
866-ARITIZE (274-8493)
Forward-looking Statements The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, "will be" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
NTAR:CC
INN Article Notification
The Conversation (0)
6h
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
600,000 New Wegovy® Pill Prescriptions Written in First Two Months KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the... Keep Reading...
15 April
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness
Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure
Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the... Keep Reading...
15 April
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization (“CRO”) to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of... Keep Reading...
15 April
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Contracts signed for Animal Study GLP-1-A26-1 KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO")... Keep Reading...
14 April
Kailera, Alamar Target Billion-Dollar Valuations in Biotech Revival
Biotechnology initial public offerings (IPOs) are regaining momentum as easing market headwinds and an appetite for weight-loss drugs coax companies back to the public markets.On Monday (April 13) Reuters reported, that obesity drug developer Kailera Therapeutics and proteomics firm Alamar... Keep Reading...
13 April
Biotech and Pharma Market Update: Q1 2026 in Review
After a strong performance toward the end of 2025, the life science sector began the new year on a constructive note. Looking forward, signals in Q1 point to a market continuing to reward proof over promise. In an interview with the Investing News Network (INN), Eric Shrayer, partner and... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00




